Cartherics, a company that focuses on allogeneic NK cell therapy, and TiCARos, a company that specializes in developing novel chimeric antigen receptor (CAR)-T cell products for the treatment of solid and blood cancers, have announced a collaboration to develop CLIP-CAR constructs for the treatment of solid tumors. The two companies will work together to assess the function of these constructs in vitro and in vivo.
TiCARos’ CLIP-CAR approach involves modifying the CAR structure to stabilize the immune synapse between immune cells and target tumor cells, resulting in enhanced efficacy. By integrating this technology with Cartherics’ platform, the two companies hope to develop more effective therapies for solid tumors.
The collaboration brings together TiCARos’ expertise in CAR-T cell therapies and Cartherics’ expertise in NK cell therapy. Together, they aim to accelerate pipeline programs and expand opportunities beyond autologous cell therapies. The partnership creates a pathway for advancing solid tumor pipeline programs and utilizing TiCARos’ technology in new ways.
Depending on the results of their research collaboration, TiCARos and Cartherics may explore development and commercialization opportunities together. This collaboration represents an exciting opportunity for both companies to advance their respective fields and potentially provide better treatments for patients with solid tumors.
